Answers are grounded in this paper and cite their sources.
<ns4:p>Histone post-translational modification (PTM) antibodies are essential research reagents in chromatin biology. However, they suffer from variable properties and insufficient documentation of quality. Antibody manufacturers and vendors should provide detailed lot-specific documentation of quality, rendering further quality checks by end-customers unnecessary. A shift from polyclonal antibodies towards sustainable reagents like monoclonal or recombinant antibodies or histone binding domains would help to improve the reproducibility of experimental work in this field.</ns4:p>
No takes yet. Share an insight, caveat, or question.
Kungulovski et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: